SCHEMBL7268508

SCHEMBL7268508

COc1cc2nc(-c3ccc(Cl)cc3)nc(N(C)C)c2cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.52
CSF1R P07333 4/20 0.52
WHR1 P49842 1/20 0.51
CYP1A2 P05177 3/20 0.49
CYP3A4 P08684 3/20 0.49
CYP2D6 P10635 3/20 0.49
USP2 O75604 2/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
MAPK1 P28482 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.47
KDM1A O60341 1/20 0.46
RCOR1 Q9UKL0 1/20 0.46
LMNA P02545 4/20 0.46
ALDH1A1 P00352 2/20 0.46
TSHR P16473 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1084322 0.86 CYP1A2 (0.52) WHR1CYP1A2CYP3A4CYP2D6USP2
SCHEMBL1083830 0.86 WHR1 (0.69) EGFRCSF1RWHR1CYP1A2CYP3A4
SCHEMBL7261412 0.85 KMT2A (0.46) EGFRCSF1RWHR1KMT2AMEN1
SCHEMBL1084170 0.85 RECQL (0.56) EGFRCSF1RWHR1CYP1A2CYP3A4
SCHEMBL7252896 0.85 MEN1 (0.56) EGFRCSF1RWHR1MAPK1KMT2A
SCHEMBL7261991 0.85 KMT2A (0.69) EGFRCSF1RWHR1KMT2AMEN1
SCHEMBL5258591 0.84 WHR1 (0.55) EGFRCSF1RWHR1MAPK1KMT2A
SCHEMBL5258730 0.82 WHR1 (0.52) EGFRCSF1RWHR1KMT2AMEN1
SCHEMBL1084011 0.82 CYP3A4 (0.60) EGFRCSF1RWHR1CYP1A2CYP3A4
SCHEMBL3320057 0.79 EGFR (0.56) EGFRCSF1RKMT2AKDM1ARCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613772-B1 Drugs such as 2-(p-chlorophenyl-4-(4-hydroxybutyl)amino-6,7,8 -trimethoxyquinazoline used for activation of guanylate cyclase and modulation of cyclic guanosine monophosphate AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-09-02 US disclosed
EP-1040101-A1 SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2000-10-04 EP disclosed
WO-1999032460-A1 SUBSTITUTED 2-ARYL-4-AMINO-CHINAZOLINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-07-01 WO disclosed